<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1111246168
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Famodine
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FAMOTIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        concentrate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HIKMA ITALIA SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HIKMA ITALIA SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in Famodine is famotidine.</p><p>Famodine, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. Famodine is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions:</p><ul><li><em>Short term treatment of active duodenal ulcer. </em>Most adult patients heal within 4 weeks; there is rarely reason to use Famodine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks.</li><li><em>Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. </em>Controlled studies in adults have not extended beyond one year.</li><li><em>Short term treatment of active benign gastric ulcer. </em>Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks.</li><li><em>Short term treatment of gastroesophageal reflux disease (GERD). </em>Famodine is indicated for short term treatment of patients with symptoms of GERD.</li><li>Famodine is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy.</li><li><em>Treatment of pathological hypersecretory conditions </em>(e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Famodine </strong></p><ul><li>If you are allergic to famotidine or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Cross sensitivity in this class of compounds has been observed. Therefore, famotidine should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Famodine.</p><p><em>General</em></p><p>Symptomatic response to therapy with famotidine does not preclude the presence of gastric malignancy.</p><p><em>Patients with moderate or severe renal insufficiency</em></p><p>Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, longer intervals between doses or lower doses may need to be used in patients with moderate (creatinine clearance &lt; 50 ml/min) or severe (creatinine clearance &lt; 10 ml/min) renal insufficiency to adjust for the longer elimination half-life of famotidine (see &ldquo;3. How to use Famodine&rdquo;).</p><p><em>Carcinogenesis, mutagenesis, impairment of fertility</em></p><p>In a 106 week study in rats and a 92 week study in mice given oral doses of up to 2000 mg/kg/day (approximately 2500 times the recommended human dose for active duodenal ulcer), there was no evidence of carcinogenic potential for famotidine.</p><p>Famotidine was negative in the microbial mutagen test (Ames test) using Salmonella typhimurium and Escherichia coli with or without rat liver enzyme activation at concentrations up to 10,000 mcg/plate. In in vivo<em> </em>studies in mice, with a micronucleus test and a chromosomal aberration test, no evidence of a mutagenic effect was observed.</p><p>In studies with rats given oral doses of up to 2000 mg/kg/day or intravenous doses of up to 200 mg/kg/day, fertility and reproductive performance were not affected.</p><p><strong>Children and adolescents</strong></p><p><em>Pediatric patients &lt; 1 year of age</em></p><p>Use of famotidine in pediatric patients &lt; 1 year of age is supported by evidence from adequate and well-controlled studies of famotidine in adults, and by the following studies in pediatric patients &lt; 1 year of age.</p><p>Two pharmacokinetic studies in pediatric patients &lt; 1 year of age (N=48) demonstrated that clearance of famotidine in patients &gt; 3 months to 1 year of age is similar to that seen in older pediatric patients (1-15 years of age) and adults. In contrast, pediatric patients 0-3 months of age had famotidine clearance values that were 2-to 4-fold less than those in older pediatric patients and adults. These studies also show that the mean bioavailability in pediatric patients &lt; 1 year of age after oral dosing is similar to older pediatric patients and adults. Pharmacodynamic data in pediatric patients 0-3 months of age suggest that the duration of acid suppression is longer compared with older pediatric patients, consistent with the longer famotidine half-life in pediatric patients 0-3 months of age.</p><p>In a double-blind, randomized, treatment-withdrawal study, 35 pediatric patients &lt; 1 year of age who were diagnosed as having gastroesophageal reflux disease were treated for up to 4 weeks with famotidine oral suspension (0.5 mg/kg/dose or 1 mg/kg/dose). Although an intravenous famotidine formulation was available, no patients were treated with intravenous famotidine in this study. Also, caregivers were instructed to provide conservative treatment including thickened feedings. Enrolled patients were diagnosed primarily by history of vomiting (spitting up) and irritability (fussiness). The famotidine dosing regimen was once daily for patients &lt; 3 months of age and twice daily for patients &ge;3 months of age. After 4 weeks of treatment, patients were randomly withdrawn from the treatment and followed an additional 4 weeks for adverse events and symptomatology. Patients were evaluated for vomiting (spitting up), irritability (fussiness) and global assessments of improvement. The study patients ranged in age at entry from 1.3 to 10.5 months (mean 5.6 &plusmn; 2.9 months), 57% were female, 91% were white and 6% were black. Most patients (27/35) continued into the treatment withdrawal phase of the study. Two patients discontinued famotidine due to adverse events. Most patients improved during the initial treatment phase of the study. Results of the treatment withdrawal phase were difficult to interpret because of small numbers of patients. Of the 35 patients enrolled in the study, agitation was observed in 5 patients on famotidine that resolved when the medication was discontinued; agitation was not observed in patients on placebo (see &ldquo;4. Possible side effects,<em> </em>Pediatric patients&rdquo;).</p><p>These studies suggest that a starting dose of 0.5 mg/kg/dose of famotidine oral suspension may be of benefit for the treatment of GERD for up to 4 weeks once daily in patients &lt; 3 months of age and twice daily in patients 3 months to &lt; 1 year of age; the safety and benefit of famotidine treatment beyond 4 weeks have not been established. Famotidine should be considered for the treatment of GERD only if conservative measures (e.g., thickened feedings) are used concurrently and if the potential benefit outweighs the risk.</p><p><em>Pediatric patients 1-16 years of age</em></p><p>Use of famotidine in pediatric patients 1-16 years of age is supported by evidence from adequate and well-controlled studies of famotidine in adults, and by the following studies in pediatric patients: In published studies in small numbers of pediatric patients 1-15 years of age, clearance of famotidine was similar to that seen in adults.</p><p>In pediatric patients 11-15 years of age, oral doses of 0.5 mg/kg were associated with a mean area under the curve (AUC) similar to that seen in adults treated orally with 40 mg. Similarly, in pediatric patients 1-15 years of age, intravenous doses of 0.5 mg/kg were associated with a mean AUC similar to that seen in adults treated intravenously with 40 mg. Limited published studies also suggest that the relationship between serum concentration and acid suppression is similar in pediatric patients 1-15 years of age as compared with adults.</p><p>These studies suggest that the starting dose for pediatric patients 1-16 years of age is 0.25 mg/kg intravenously (injected over a period of not less than two minutes or as a 15-minute infusion) every 12 hours up to 40 mg/day. While published uncontrolled clinical studies suggest effectiveness of famotidine in the treatment of peptic ulcer, data in pediatric patients are insufficient to establish percent response with dose and duration of therapy.</p><p>Therefore, treatment duration (initially based on adult duration recommendations) and dose should be individualized based on clinical response and/or gastric pH determination and endoscopy. Published uncontrolled studies in pediatric patients have demonstrated gastric acid suppression with doses up to 0.5 mg/kg intravenously every 12 hours.</p><p><strong>Other medicines and Famodine</strong></p><p>Tell your doctor or pharmacist if you are taking have recently taken or might take any other medicines.</p><p>No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro<em> </em>have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.</p><p><strong>Geriatric Use</strong></p><p>Of the 4,966 subjects in clinical studies who were treated with famotidine, 488 subjects (9.8%) were 65 and older, and 88 subjects (1.7%) were greater than 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, greater sensitivity of some older patients cannot be ruled out.</p><p>No dosage adjustment is required based on age. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Dosage adjustment in the case of moderate or severe renal impairment is necessary (see Warnings and precautions, Patients with Moderate or Severe Renal Insufficiency and 3. How to use Famodine, Dosage Adjustment for Patients with Moderate or Severe Renal Insufficiency).</p><p><strong>Pregnancy and breast-feeding </strong></p><p><em>Pregnancy</em></p><p>Pregnancy Category B.</p><p>Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day, respectively, and in both species at I.V. doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (250 times the usual human dose) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p><em>Nursing Mothers</em></p><p>Studies performed in lactating rats have shown that famotidine is secreted into breast milk. Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of at least 600 times the usual human dose. Famotidine is detectable in human milk. Because of the potential for serious adverse reactions in nursing infants from famotidine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>In some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or in patients who are unable to take oral medication, Famodine may be administered until oral therapy can be instituted.</p><p>The recommended dosage for Famodine in adult patients is 20 mg intravenously every 12 hours.</p><p>The doses and regimen for parenteral administration in patients with GERD have not been established.</p><p><strong>Dosage for pediatric patients &lt; 1 year of age gastroesophageal reflux disease (GERD)</strong></p><p>See &ldquo;2.&nbsp; What you need to know before you use Famodine, Children and adolescents, Pediatric patients &lt; 1 year of age&rdquo;.</p><p>The studies described in Children and adolescents, Pediatric Patients &lt; 1 year of age suggest the following starting doses in pediatric patients &lt; 1 year of age: Gastroesophageal Reflux Disease (GERD) - 0.5 mg/kg/dose of famotidine oral suspension for the treatment of GERD for up to 8 weeks once daily in patients &lt; 3 months of age and 0.5 mg/kg/dose twice daily in patients 3 months to &lt; 1 year of age. Patients should also be receiving conservative measures (e.g., thickened feedings). The use of intravenous famotidine in pediatric patients &lt; 1 year of age with GERD has not been adequately studied.</p><p><strong>Dosage for pediatric patients 1-16 years of age</strong></p><p>See &ldquo;2.&nbsp; What you need to know before you use Famodine, Children and adolescents, Pediatric patients 1-16 years of age&rdquo;.</p><p>The studies described in Warnings and precautions, Pediatric Patients 1-16 years of age suggest that the starting dose in pediatric patients 1-16 years of age is 0.25 mg/kg intravenously (injected over a period of not less than two minutes or as a 15-minute infusion) every 12 hours up to 40 mg/day.</p><p>While published uncontrolled clinical studies suggest effectiveness of famotidine in the treatment of peptic ulcer, data in pediatric patients are insufficient to establish percent response with dose and duration of therapy. Therefore, treatment duration (initially based on adult duration recommendations) and dose should be individualized based on clinical response and/or gastric pH determination and endoscopy. Published uncontrolled studies in pediatric patients 1-16 years of age have demonstrated gastric acid suppression with doses up to 0.5 mg/kg intravenously every 12 hours.</p><p><strong>Dosage adjustments for patients with moderate or severe renal insufficiency</strong></p><p>In adult patients with moderate (creatinine clearance &lt; 50 ml/min) or severe (creatinine clearance &lt; 10 ml/min) renal insufficiency, the elimination half-life of famotidine is increased. For patients with severe renal insufficiency, it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the drug in patients with moderate or severe renal insufficiency, the dose of Famodine may be reduced to half the dose, or the dosing interval may be prolonged to 36-48 hours as indicated by the patient&#39;s clinical response.</p><p>Based on the comparison of pharmacokinetic parameters for famotidine in adults and pediatric patients, dosage adjustment in pediatric patients with moderate or severe renal insufficiency should be considered.</p><p><strong>Pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine adenomas)</strong></p><p>The dosage of Famodine in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult intravenous dose is 20 mg every 12 hours. Doses should be adjusted to individual patient needs and should continue as long as clinically indicated. In some patients, a higher starting dose may be required. Oral doses up to 160 mg every 6 hours have been administered to some adult patients with severe Zollinger-Ellison Syndrome.</p><p><strong>Concomitant use of antacids</strong></p><p>Antacids may be given concomitantly if needed.</p><p><strong>If you use more Famodine than you should</strong></p><p>The adverse reactions in overdose cases are similar to the adverse reactions encountered in normal clinical experience (see 4. Possible side effects).<strong> </strong>Oral doses of up to 640 mg/day have been given to adult patients with pathological hypersecretory conditions with no serious adverse effects. In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed.</p><p>The intravenous LD<sub>50</sub> of famotidine for mice and rats ranged from 254-563 mg/kg and the minimum lethal single I.V. dose in dogs was approximately 300 mg/kg. Signs of acute intoxication in I.V. treated dogs were emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse. The oral LD<sub>50</sub> of famotidine in male and female rats and mice was greater than 3000 mg/kg and the minimum lethal acute oral dose in dogs exceeded 2000 mg/kg. Famotidine did not produce overt effects at high oral doses in mice, rats, cats and dogs, but induced significant anorexia and growth depression in rabbits starting with 200 mg/kg/day orally.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The adverse reactions listed below have been reported during domestic and international clinical trials in approximately 2500 patients. In those controlled clinical trials in which famotidine tablets were compared to placebo, the incidence of adverse experiences in the group which received famotidine tablets, 40 mg at bedtime, was similar to that in the placebo group.</p><p>The following adverse reactions have been reported to occur in more than 1% of patients on therapy with famotidine in controlled clinical trials, and may be causally related to the drug: headache (4.7%), dizziness (1.3%), constipation (1.2%) and diarrhea (1.7%).</p><p>The following other adverse reactions have been reported infrequently in clinical trials or since the drug was marketed. The relationship to therapy with famotidine has been unclear in many cases. Within each category the adverse reactions are listed in order of decreasing severity:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Body as a Whole:</em></p></td><td style="vertical-align:top"><p>Fever, asthenia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiovascular:</em></p></td><td style="vertical-align:top"><p>Arrhythmia, AV block, palpitation</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal:</em></p></td><td style="vertical-align:top"><p>Cholestatic jaundice, liver enzyme abnormalities, vomiting, nausea, abdominal discomfort, anorexia, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p><em>Hematologic:</em></p></td><td style="vertical-align:top"><p>Rare cases of agranulocytosis, pancytopenia, leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Hypersensitivity:</em></p></td><td style="vertical-align:top"><p>Anaphylaxis, angioedema, orbital or facial edema, urticaria, rash, conjunctival injection</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal:</em></p></td><td style="vertical-align:top"><p>Musculoskeletal pain including muscle cramps, arthralgia</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous System/Psychiatric:</em></p></td><td style="vertical-align:top"><p>Grand mal seizure; psychic disturbances, which were reversible in cases for which follow-up was obtained, including hallucinations, confusion, agitation, depression, anxiety, decreased libido; paresthesia; insomnia; somnolence. Convulsions, in patients with impaired renal function, have been reported very rarely.</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory:</em></p></td><td style="vertical-align:top"><p>Bronchospasm, interstitial pneumonia</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin:</em></p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis/Stevens Johnson syndrome (very rare), alopecia, acne, pruritus, dry skin, flushing</p></td></tr><tr><td style="vertical-align:top"><p><em>Special Senses:</em></p></td><td style="vertical-align:top"><p>Tinnitus, taste disorder</p></td></tr><tr><td style="vertical-align:top"><p><em>Other:</em></p></td><td style="vertical-align:top"><p>Rare cases of impotence and rare cases of gynecomastia have been reported; however, in controlled clinical trials, the incidences were not greater than those seen with placebo.</p></td></tr></tbody></table><p>The adverse reactions reported for famotidine tablets may also occur with famotidine for oral suspension and famotidine injection. In addition, transient irritation at the injection site has been observed with famotidine injection.</p><p><em>Pediatric Patients</em></p><p>In a clinical study in 35 pediatric patients &lt; 1 year of age with GERD symptoms [e.g., vomiting (spitting up), irritability (fussing)], agitation was observed in 5 patients on famotidine that resolved when the medication was discontinued.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package.</p><p><em>After dilution: </em></p><p>Diluted Famodine injection is physically and chemically stable for 7 days at room temperature. Although diluted Famodine injection has been shown to be physically and chemically stable for 7 days at room temperature, there are no data on the maintenance of sterility after dilution. Therefore, it is recommended that if not used immediately after preparation, diluted solutions of Famodine injection should be refrigerated and used within 48 hours.</p><p>Do not use this medicine after the expiry date which is stated on the package &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is famotidine.</p><p>Each 2 ml of Famodine 20 mg/2 ml Concentrate for Solution for Injection contains 20 mg famotidine.</p><p>The other ingredients are aspartic acid, mannitol and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Famodine 20 mg/2 ml Concentrate for Solution for Injection is a clear, colorless to slightly yellow solution in 2 ml type I clear glass ampoules with black one-point-cut.
Pack size: 5 Ampoules (2 ml).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser </strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road</p><p>P.O. Box 106229</p><p>Riyadh 11666, Saudi Arabia</p><p>Tel: + (966-11) 8107023, + (966-11) 2142472</p><p>Fax: + (966-11) 2078170</p><p>e-mail: SAPV@hikma.com</p><p><strong>Bulk manufacturer</strong></p><p>Hikma Italia S.P.A.<br />Viale Certosa, 10<br />27100 Pavia, Italy<br />Tel: + (39-0382) 1751844/+ (39-0382) 1751801<br />Fax: + (39-0382) 422745</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03/2023; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في فامودين هي فاموتيدين.</p><p dir="RTL">يعد فامودين، الذي يتم توفيره كمحلول مركز للحقن الوريدي، مخصصاً للاستخدام الوريدي فقط. يُوصى باستخدام فامودين لدى بعض المرضى المقيمين في المستشفيات الذين يعانون من حالات فرط الإفراز المرضي أو القرح المستعصية، أو كبديل لأشكال الجرعات الفموية للاستخدام قصير المدى لدى المرضى غير القادرين على تناول الأدوية عن طريق الفم للحالات التالية:</p><ul dir="rtl"><li><em>العلاج قصير المدى لقرحة الاثني عشر النشطة. </em>يتعافى معظم المرضى البالغين في غضون 4 أسابيع؛ ونادراً ما يوجد سبب لاستخدام فامودين بجرعة كاملة لمدة تزيد على 6 إلى 8 أسابيع. لم تقيّم الدراسات سلامة فاموتيدين في علاج قرحة الاثني عشر النشطة غير المعقدة لفترات تتخطى ثمانية أسابيع.<em> </em></li><li><em>علاج المداومة لمرضى قرحة الاثني عشر بجرعات مُخفَّضة بعد شفائهم من القرحة النشطة. </em>لم تمتد الدراسات الخاضعة للرقابة التي أُجريت على البالغين لأكثر من عام واحد.<em> </em></li><li><em>العلاج قصير المدى لقرحة المعدة الحميدة النشطة. </em>يتعافى معظم المرضى البالغين في غضون 6 أسابيع. لم تقيّم الدراسات سلامة فاموتيدين أو فاعليته في علاج قرحة المعدة الحميدة النشطة غير المعقدة لفترات تتخطى 8 أسابيع.<em> </em></li><li><em>العلاج قصير المدى لمرض الارتجاع المعدي المريئي. </em>يُوصى باستخدام فامودين للعلاج قصير المدى للمرضى الذين يعانون من أعراض الارتجاع المعدي المريئي.</li></ul><p dir="RTL">كما يُوصى باستخدام فامودين للعلاج قصير المدى لالتهاب المريء الناتج عن الارتجاع المعدي المريئي، بما في ذلك مرض التآكل أو التقرح الذي يتم تشخيصه عن طريق التنظير الباطني.</p><p><em>علاج حالات فرط الإفراز المرضي </em>(على سبيل المثال، متلازمة زولينجر إليسون، أورام الغدد الصماء المتعددة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم فامودين </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لفاموتيدين أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li></ul><p dir="RTL">لوحظ وجود حساسية متزامنة في هذه الفئة من المركبات. لذلك، يجب عدم إعطاء فاموتيدين للمرضى الذين لديهم تاريخ من فرط التحسس لمضادات مستقبلات الهيستامين 2 الأخرى.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي، أو الممرض قبل استخدام فامودين.</p><p dir="RTL"><em>عامة</em></p><p dir="RTL">لا تمنع الاستجابة العرضية للعلاج بفاموتيدين وجود ورم خبيث في المعدة.</p><p dir="RTL"><em>المرضى الذين يعانون من قصور كلوي متوسط أو شديد</em></p><p dir="RTL">حيث أنه تم الإبلاغ عن آثار ضائرة على الجهاز العصبي المركزي لدى المرضى الذين يعانون من قصور كلوي متوسط أو شديد، قد يتطلب الأمر ترك فواصل زمنية أطول بين الجرعات أو استخدام جرعات منخفضة أكثر لدى المرضى الذين يعانون من قصور كلوي معتدل (تصفية الكرياتينين &lt; 50 مللتر/دقيقة) أو شديد (تصفية الكرياتينين &gt; 10 مللتر/دقيقة) للتكيف مع فترة عمر النصف الأطول للتخلص من فاموتيدين (انظر &quot;3. طريقة استخدام فامودين&quot;).</p><p dir="RTL"><em>التسرطن، التطفير، وضعف الخصوبة</em></p><p dir="RTL">في دراسة أجريت على الجرذان امتدت 106 أسابيع وأخرى استمرت 92 أسبوعاً على الفئران التي أُعطيت جرعات فموية تصل إلى 2000 ملغم/كغم/يوم (ما يقرب من 2500 ضعف الجرعة البشرية الموصى بها لقرحة الاثني عشر النشطة)، لم يكن هناك دليل على إمكانية الإصابة بالسرطان جراء استخدام فاموتيدين.</p><p dir="RTL">سجل فاموتيدين نتيجة سلبية في اختبار الطفرات الجرثومية (اختبار أيمز) باستخدام السالمونيلا التيفية الفأرية والإشريكية القولونية مع أو بدون تنشيط إنزيم كبد الجرذان بتركيزات تصل إلى 10000 مكغم/شريحة. في دراسات مختبرية<em> </em>أُجريت على الفئران، مع اختبار النواة الدقيقة واختبار انحراف الكروموسومات، لم يلاحظ أي دليل على وجود تأثير مُطفر.</p><p dir="RTL">في الدراسات التي أجريت على الجرذان التي أعطيت جرعات فموية تصل إلى 2000 ملغم/كغم/يوم أو جرعات في الوريد تصل إلى 200 ملغم/كغم/يوم، لم تتأثر الخصوبة والأداء الإنجابي.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><em>مرضى الأطفال الذين تقل أعمارهم عن عام واحد</em></p><p dir="RTL">يأتي استخدام فاموتيدين لدى المرضى الأطفال الذين تقل أعمارهم عن عام واحد مدعوماً بأدلة مستقاة من دراسات كافية ومراقبة جيداً أُجريت على استخدام فاموتيدين لدى البالغين، ومن خلال الدراسات التالي ذكرها التي أُجريت على المرضى الأطفال الذين تقل أعمارهم عن عام واحد.</p><p dir="RTL">أظهرت دراستان عن الحرائك الدوائية لدى المرضى الأطفال الذين تقل أعمارهم عن عام واحد (العدد = 48) أن تصفية فاموتيدين لدى المرضى الذين تزيد أعمارهم على 3 أشهر إلى عام واحد مشابهة لتلك التي لوحظت لدى المرضى الأطفال الأكبر سناً (الذين تتراوح أعمارهم بين عام واحد و15 عاماً) والبالغين. في المقابل، كان لدى المرضى الأطفال الذين تتراوح أعمارهم بين 0 و3 أشهر قيم تصفية فاموتيدين أقل بمقدار 2 إلى 4 أضعاف من تلك الموجودة لدى المرضى الأطفال الأكبر سناً والبالغين. كما تُظهر هذه الدراسات أن متوسط التوافر البيولوجي لدى المرضى الأطفال الذين تقل أعمارهم عن عام واحد بعد تلقي الجرعات الفموية مشابه للمرضى الأطفال الأكبر سناً والبالغين. تشير البيانات الديناميكية الدوائية لدى المرضى الأطفال الذين تتراوح أعمارهم بين 0 و3 أشهر إلى أن مدة قمع الحمض أطول مقارنة بالمرضى الأطفال الأكبر سناً، بما يتوافق مع فترة عمر النصف الأطول لفاموتيدين لدى المرضى الأطفال الذين تتراوح أعمارهم بين 0 إلى 3 أشهر.</p><p dir="RTL">في دراسة بشأن الانسحاب من العلاج مزدوجة التعمية، عشوائية، تم علاج 35 مريضاً من الأطفال الذين تقل أعمارهم عن عام واحد ممن جرى تشخيصهم بمرض الارتجاع المعدي المريئي لمدة تصل إلى 4 أسابيع باستخدام معلق فاموتيدين الفموي (0,5 ملغم/كغم/الجرعة أو 1 ملغم/كغم/الجرعة). على الرغم من توفر تركيبة فاموتيدين الوريدية، لم يتم علاج أي مرضى بإعطاء فاموتيدين عبر الوريد في هذه الدراسة. كما تم توجيه مقدمي الرعاية لتوفير العلاج التحفظي بما في ذلك التغذية السميكة. تم تشخيص المرضى المسجلين في الأساس عن طريق تاريخ القيء (البصق) والتهيج (الانزعاج). تمثَّل نظام جرعات فاموتيدين في إعطاء جرعة واحدة يومياً للمرضى الذين تقل أعمارهم عن 3 أشهر وجرعتين يومياً للمرضى الذين تبلغ أعمارهم 3 أشهر أو أكثر. بعد 4 أسابيع من العلاج، تم إيقاف المرضى عشوائياً عن تناول العلاج ومتابعتهم لمدة 4 أسابيع إضافية لترقب ظهور أي آثار عكسية أو أعراض. تم تقييم المرضى من حيث القيء (البصق) والتهيج (الانزعاج) وتقييمات التحسن الشاملة. تراوحت أعمار المرضى المشاركين في الدراسة عند الدخول بين 1,3 و10,5 أشهر (متوسط 5,6 &plusmn; 2,9 أشهر)، وبلغت نسبة المشاركات الإناث 57% وجاءت نسبة المشاركين من ذوي البشرة البيضاء 91% و6% من ذوي البشرة السمراء. استمر معظم المرضى (27/35) في الدراسة حتى مرحلة الانسحاب من العلاج. توقف مريضان عن تناول فاموتيدين بسبب الآثار العكسية. تحسن معظم المرضى خلال مرحلة العلاج الأولي من الدراسة. كان من الصعب تفسير نتائج مرحلة الانسحاب من العلاج بسبب قلة عدد المرضى. من بين 35 مريضاً شاركوا في الدراسة، لوحظ حدوث تهيج لدى 5 مرضى تناولوا فاموتيدين والذي تلاشى بمجرد التوقف عن تناول الدواء؛ لم يلاحظ التهيج لدى المرضى الذين يتناولون الدواء الوهمي (انظر &quot;4. الآثار الجانبية المحتملة، المرضى الأطفال&quot;).</p><p>تشير هذه الدراسات إلى أن جرعة البدء التي تبلغ 0,5 ملغم/كغم/جرعة من معلق فاموتيدين الفموي قد تكون مفيدة لعلاج الارتجاع المعدي المريئي لمدة تصل إلى 4 أسابيع مأخوذة مرة واحدة يومياً لدى المرضى الذين تقل أعمارهم عن 3 أشهر، وجرعتين يومياً لدى المرضى من 3 أشهر إلى أقل من عام واحد، لم يتم تحديد سلامة وفائدة علاج فاموتيدين بعد 4 أسابيع. يجب التفكير في استخدام فاموتيدين لعلاج الارتجاع المعدي المريئي فقط إذا تم اتباع التدابير المحافظة (مثل التغذية السميكة) بشكل متزامن وإذا كانت الفوائد المحتملة تفوق المخاطر.</p><p dir="RTL"><em>مرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً</em></p><p dir="RTL">يأتي استخدام فاموتيدين لدى مرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً مدعوماً بأدلة مستقاة من دراسات كافية ومراقبة جيداً أُجريت على استخدام فاموتيدين لدى البالغين، وبالدراسات التالية التي أُجريت على المرضى الأطفال: في الدراسات المنشورة على أعداد صغيرة من المرضى الأطفال الذين تتراوح أعمارهم بين عام و15 عاماً، كانت تصفية فاموتيدين مشابهة لتلك التي لوحظت لدى البالغين.</p><p dir="RTL">لدى المرضى الأطفال الذين تتراوح أعمارهم بين 11 و15 عاماً، ارتبطت الجرعات الفموية البالغة 0,5 ملغم/كغم بمتوسط مساحة تحت المنحنى مماثل لذلك الذي يظهر لدى البالغين الذين تلقوا العلاج عن طريق الفم بجرعة 40 ملغم. وعلى نحو مماثل، لدى المرضى الأطفال الذين تتراوح أعمارهم بين عام و15 عاماً، ارتبطت الجرعات الوريدية بمقدار 0,5 ملغم/كغم مع متوسط مساحة تحت المنحنى مماثل لذلك الذي يظهر لدى البالغين الذين تلقوا العلاج عن طريق الوريد بجرعة 40 ملغم. كما تشير الدراسات المنشورة المحدودة إلى أن العلاقة بين تركيز المصل وقمع الحمض متشابهة لدى المرضى الأطفال الذين تتراوح أعمارهم بين عام و15 عاماً مقارنةً بالبالغين.</p><p dir="RTL">وتشير هذه الدراسات إلى أن جرعات البدء لمرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً تبلغ 0,25 ملغم/كغم تُعطى عن طريق الوريد (تُحقن في مدة لا تقل عن دقيقتين أو يتم تسريبها على مدار 15 دقيقة) كل 12 ساعة وتصل إلى 40 ملغم/يوم. بينما تشير الدراسات السريرية غير المقيدة المنشورة إلى فاعلية فاموتيدين في علاج القرحة الهضمية، فإن البيانات لدى المرضى الأطفال غير كافية لتحديد نسبة الاستجابة مع الجرعة ومدة العلاج.</p><p dir="RTL">لذلك، ينبغي تحديد مدة العلاج (تستند في الأساس على توصيات المدة للبالغين) والجرعة على نحو فردي بناءً على الاستجابة السريرية و/أو تحديد الرقم الهيدروجيني في المعدة والتنظير الباطني. أظهرت دراسات غير مقيدة منشورة أجريت على مرضى أطفال قمع حمض المعدة باستخدام جرعات تصل إلى 0,5 ملغم/كغم تُعطى عن طريق الوريد كل 12 ساعة.</p><p dir="RTL"><strong>الأدوية الأخرى وفامودين</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">لم يتم تحديد أي تفاعلات دوائية. أظهرت الدراسات التي أجريت على فاموتيدين مع البشر، في النماذج الحيوانية <em>وفي المختبر </em>عدم وجود تداخل ملحوظ مع التخلص من المركبات التي يتم استقلابها بواسطة الإنزيمات الميكروسومية الكبدية، على سبيل المثال، نظام سيتوكروم P450. تشمل المركبات التي تم اختبارها على الإنسان الوارفارين، الثيوفيلين، الفينيتوين، الديازيبام، الأمينوبيرين والأنتيبيرين. تم اختبار الإندوسيانين الأخضر كمؤشر لاستخراج الأدوية الكبدية ولم يتم العثور على تأثيرات ملحوظة.</p><p dir="RTL"><strong>الاستخدام لدى كبار السن</strong></p><p dir="RTL">بلغ عدد الأشخاص المشاركين في هذه الدراسات السريرية 4966 حالة خضعوا للعلاج باستخدام الفاموتيدين، وكان من بينهم 488 حالة (9,8%) في عمر 65 عاماً فيما فوق و88 حالة (1,7%) تزيد أعمارهم على 75 عاماً. لم يُلاحظ أي فروق شاملة بشأن السلامة أو الفاعلية بين هؤلاء الأشخاص ومن يصغرهم سناً. ومع ذلك، لا يمكن استبعاد زيادة الحساسية لدى بعض المرضى الأكبر سناً.</p><p dir="RTL">لا يلزم تعديل الجرعة بناءً على العمر. يُعرف هذا الدواء بأن الكلى تتخلص منه بدرجة كبيرة، وقد يتزايد خطر حدوث تفاعلات سامة لهذا العقار بين المرضى المصابين بضعف وظائف الكلى. ولأن المرضى كبار السن أكثر عرضة لانخفاض كفاءة وظائف الكلى، يجب الحرص عند اختيار الجرعة. وقد يفيد أيضاً القيام بمراقبة وظائف الكلى لديهم. يلزم تعديل الجرعة في حالة الضعف الكلوي المتوسط أو الحاد (انظر الاحتياطات والتحذيرات، المرضى الذين يعانون من قصور كلوي متوسط أو حاد، و3. طريقة استخدام فامودين، تعديل الجرعة للمرضى الذين يعانون من قصور كلوي متوسط أو شديد).</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL"><em>الحمل</em></p><p dir="RTL">الحمل فئة ب.</p><p dir="RTL">أُجريت دراسات الإنجاب على الجرذان والأرانب بجرعات فموية تصل إلى 2000 و500 ملغم/كغم/يوم على التوالي، وفي كلا النوعين بجرعات وريدية تصل إلى 200 ملغم/كغم/يوم، ولم يتم الكشف عن أي أدلة مهمة على ضعف الخصوبة أو ضرر للجنين بسبب فاموتيدين. رُغم عدم وجود آثار سمية مباشرة للجنين، فقد لوحظت عمليات إجهاض متفرقة تحدث فقط لدى الأمهات اللواتي أظهرن انخفاضاً ملحوظاً في المدخول الغذائي في بعض الأرانب عند تناول جرعات فموية قدرها 200 ملغم/كغم/يوم (250 ضعف الجرعة المعتادة للإنسان) أو أعلى. ومع ذلك، لم تُجرى أي دراسات وافية أو مضبوطة جيداً على النساء الحوامل. ولأن الدراسات الإنجابية التي أُجريت على الحيوانات لا تنبئ دائماً بالاستجابة البشرية، فلا ينبغي استخدام هذا الدواء أثناء الحمل إلا إذا كانت هناك حاجة واضحة لذلك.</p><p dir="RTL"><em>الأمهات المرضعات</em></p><p dir="RTL">أظهرت الدراسات التي أُجريت على الجرذان المرضعة أن دواء فاموتيدين يُفرز في حليب الثدي. لوحظ ضعف النمو العابر لدى الجرذان الصغيرة التي ترضع من أمهات عولجن بجرعات مسممة للأم لا تقل عن 600 ضعف الجرعة البشرية المعتادة. يظهر فاموتيدين في حليب الإنسان. بسبب احتمالية حدوث تفاعلات عكسية خطيرة لدى الأطفال الرُضع بسبب فاموتيدين، يجب اتخاذ قرار بشأن التوقف عن الإرضاع أو التوقف عن تناول الدواء، مع الأخذ في الاعتبار مدى أهمية الدواء بالنسبة للأم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بالنسبة لبعض المرضى المقيمين في المستشفيات الذين يعانون من حالات فرط الإفراز المرضي أو القرح المستعصية، سأو المرضى غير القادرين على تناول الأدوية عن طريق الفم، يمكن إعطاء فامودين حتى يمكن بدء العلاج عن طريق الفم.</p><p dir="RTL">تبلغ جرعة فامودين الموصى بها لدى المرضى البالغين 20 ملغم تعطى في الوريد كل 12 ساعة.</p><p dir="RTL">لم يتم تحديد الجرعات وطريقة الإعطاء بالحقن لدى مرضى الارتجاع المعدي المريئي.</p><p dir="RTL"><strong>الجرعة المخصصة للمرضى الأطفال الذين تقل أعمارهم عن عام واحد ويعانون من مرض الارتجاع المعدي المريئي</strong></p><p dir="RTL">انظر &quot;2. ما الذي يجب عليك معرفته قبل استخدام فامودين، الأطفال والمراهقون، المرضى الأطفال الذين تقل أعمارهم عن عام واحد&quot;.</p><p dir="RTL">تُشير الدراسات الموضحة في قسم الأطفال والمراهقين، المرضى الأطفال الذين تقل أعمارهم عن عام واحد، إلى استخدام جرعات البدء التالية لدى المرضى الأطفال الذين تقل أعمارهم عن عام واحد: مرض الارتجاع المعدي المريئي - 0,5 ملغم/كغم/جرعة من معلق فاموتيدين الفموي لعلاج الارتجاع المعدي المريئي لمدة تصل إلى 8 أسابيع تؤخذ مرة واحدة يومياً لدى المرضى الذين تقل أعمارهم عن 3 أشهر، و0,5 ملغم/كغم/جرعة تؤخذ مرتين يومياً لدى المرضى الذين تتراوح أعمارهم بين 3 أشهر وعام. يجب أن يتلقى المرضى أيضاً تدابير وقائية (مثل التغذية السميكة). لم يخضع استخدام فاموتيدين عن طريق الوريد لدى المرضى الأطفال الذين تقل أعمارهم عن عام واحد ويعانون من الارتجاع المعدي المريئي للدراسة الوافية.</p><p dir="RTL"><strong>جرعة المرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً</strong></p><p dir="RTL">انظر &quot;2. ما الذي يجب عليك معرفته قبل استخدام فامودين، الأطفال والمراهقون، المرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً&quot;.</p><p dir="RTL">تشير الدراسات الموضحة في الاحتياطات والتحذيرات، المرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً، إلى أن جرعة البدء لدى المرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً تبلغ 0,25 ملغم/كغم عن طريق الوريد (يتم حقنها خلال مدة لا تقل عن دقيقتين أو تسريبها على مدار 15 دقيقة) كل 12 ساعة حتى 40 ملغم/يوم.</p><p dir="RTL">بينما تشير الدراسات السريرية غير المقيدة المنشورة إلى فاعلية فاموتيدين في علاج القرحة الهضمية، فإن البيانات لدى المرضى الأطفال غير كافية لتحديد نسبة الاستجابة مع الجرعة ومدة العلاج. لذلك، ينبغي تحديد مدة العلاج (تستند في الأساس على توصيات المدة للبالغين) والجرعة على نحو فردي بناءً على الاستجابة السريرية و/أو تحديد الرقم الهيدروجيني في المعدة والتنظير الباطني. أظهرت الدراسات غير المقيدة المنشورة التي أجريت على المرضى الأطفال الذين تتراوح أعمارهم بين عام و16 عاماً قمع حمض المعدة باستخدام جرعات تصل إلى 0,5 ملغم/كغم عن طريق الوريد كل 12 ساعة.</p><p dir="RTL"><strong>تعديلات الجرعة للمرضى الذين يعانون من قصور كلوي متوسط أو شديد</strong></p><p dir="RTL">لدى المرضى البالغين الذين يعانون من قصور كلوي متوسط (تصفية الكرياتينين &lt; 50 مللتر/دقيقة) أو شديد (تصفية الكرياتينين &lt; 10 مللتر/دقيقة)، تزداد فترة عمر النصف للتخلص من فاموتيدين. بالنسبة للمرضى الذين يعانون من قصور كلوي شديد، قد تتخطى فترة عمر النصف 20 ساعة، وتصل إلى ما يقرب من 24 ساعة لدى مرضى انقطاع البول. بعد الإبلاغ عن آثار ضائرة على الجهاز العصبي المركزي لدى المرضى الذين يعانون من قصور كلوي متوسط وشديد، لتجنب التراكم الزائد للدواء لدى المرضى الذين يعانون من قصور كلوي متوسط أو شديد، يمكن تقليل جرعة فامودين إلى النصف أو زيادة الفاصل الزمني بين الجرعات إلى 36-48 ساعة على النحو الذي توضحه الاستجابة السريرية للمريض.</p><p dir="RTL">واستناداً إلى مقارنة معلمات الحرائك الدوائية لفاموتيدين لدى البالغين ومرضى الأطفال، ينبغي مراعاة تعديل الجرعة لدى مرضى الأطفال المصابين بقصور كلوي معتدل أو شديد.</p><p dir="RTL"><strong>حالات فرط الإفراز المرضي (على سبيل المثال، متلازمة زولينجر إليسون، أورام الغدد الصماء المتعددة)</strong></p><p dir="RTL">تختلف جرعة فامودين لدى المرضى الذين يعانون من حالات فرط الإفراز المرضي من مريض لآخر. تبلغ الجرعة الوريدية للبالغين الموصى بها 20 ملغم كل 12 ساعة. ينبغي تعديل الجرعات حسب احتياجات كل مريض، وينبغي مواصلتها ما دام كان ذلك مطلوباً من الناحية السريرية. قد يتطلب بعض المرضى جرعة بدء أعلى. تم إعطاء جرعات فموية تصل إلى 160 ملغم كل 6 ساعات لبعض المرضى البالغين المصابين بمتلازمة زولينجر إليسون الشديدة.</p><p dir="RTL"><strong>الاستخدام المصاحب لمضادات الحموضة</strong></p><p dir="RTL">يمكن إعطاء الأدوية المضادة للحموضة بالتزامن إذا لزم الأمر.</p><p dir="RTL"><strong>إذا استخدمت فامودين أكثر من اللازم</strong></p><p dir="RTL">تشبه التفاعلات الضائرة في حالات تلقي جرعة زائدة التفاعلات الضائرة التي تمت مواجهتها في التجارب السريرية العادية (انظر 4. الآثار الجانبية المحتملة). تم إعطاء جرعات فموية تصل إلى 640 ملغم/يوم للمرضى البالغين الذين يعانون من حالات فرط الإفراز المرضي ولم تظهر أي تأثيرات ضائرة خطيرة. في حالة الجرعة الزائدة، ينبغي أن يكون العلاج عرضياً وداعماً. ينبغي التخلص من المواد غير الممتصة من القناة الهضمية ومراقبة المريض واستخدام العلاج الداعم.</p><p dir="RTL">تراوحت الجرعة المميتة التي تُعطى عن طريق الوريد من فاموتيدين للفئران والجرذان من 254 إلى 563 ملغم/كغم، فيما بلغ الحد الأدنى للجرعة الفردية الوريدية المميتة في الكلاب حوالي 300 ملغم/كغم. كانت علامات التسمم الحاد في الكلاب المُعالَجة عن طريق الوريد هي التقيؤ، الاضطراب، شحوب الأغشية المخاطية أو احمرار الفم والأذنين، انخفاض ضغط الدم، تسارع نبض القلب والانهيار. كانت الجرعة المميتة التي تُعطى عن طريق الفم من فاموتيدين في ذكور وإناث الجرذان والفئران أكبر من 3000 ملغم/كغم، وتجاوز الحد الأدنى للجرعة الفموية الحادة المميتة في الكلاب 2000 ملغم/كغم. لم يُحدث فاموتيدين تأثيرات واضحة عند تناول جرعات فموية عالية في الفئران، الجرذان، القطط والكلاب، إلا أنه تسبب في فقدان الشهية وضعف النمو في الأرانب بدءاً من جرعة 200 ملغم/كغم/يوم عن طريق الفم.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب، الصيدلي، أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">تم الإبلاغ عن التفاعلات الضائرة المذكورة أدناه خلال التجارب السريرية المحلية والدولية لنحو 2500 مريض. في تلك التجارب السريرية المضبوطة التي تمت فيها مقارنة أقراص فاموتيدين مع الدواء الوهمي، جاءت نسبة حدوث التجارب الضائرة في المجموعة التي تلقت أقراص فاموتيدين 40 ملغم عند النوم، مماثلة للنسبة المسجلة في المجموعة التي تناولت الدواء الوهمي.</p><p dir="RTL">تم الإبلاغ عن حدوث التفاعلات الضائرة التالية لدى أكثر من 1% من المرضى الذين يتلقون العلاج باستخدام فاموتيدين في التجارب السريرية الخاضعة للرقابة، وقد ترتبط ارتباطاً سببياً بالدواء: الصداع (4,7%)، الدوخة (1,3%)، الإمساك (1,2%) والإسهال (1,7%).</p><p dir="RTL">تم الإبلاغ عن التفاعلات الضائرة الأخرى التالية بشكل غير متكرر في التجارب السريرية أو منذ طرح الدواء في الأسواق. لم تتضح العلاقة مع العلاج باستخدام فاموتيدين في كثير من الحالات. ضمن كل فئة، تم سرد التفاعلات الضائرة مرتبة تنازلياً إلى الأقل شدة:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>الجسم ككل:</em></p></td><td style="vertical-align:top"><p dir="RTL">الحمى، الوهن، التعب</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>القلب والأوعية الدموية:</em></p></td><td style="vertical-align:top"><p dir="RTL">عدم انتظام نبضات القلب، الإحصار الأذيني البطيني، الخفقان</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>التأثيرات المعدية المعوية:</em></p></td><td style="vertical-align:top"><p dir="RTL">اليرقان الركودي، تشوهات إنزيم الكبد، القيء، الغثيان، عدم الراحة في البطن،</p><p dir="RTL">فقدان الشهية، جفاف الفم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>تأثيرات الدم:</em></p></td><td style="vertical-align:top"><p dir="RTL">حالات نادرة من ندرة المحببات، قلة الكريات الشاملة، قلة الكريات البيضاء، قلة الصفيحات</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>فرط التحسس:</em></p></td><td style="vertical-align:top"><p dir="RTL">التأق، الوذمة الوعائية، الوذمة المدارية أو الوجهية، الشرى، الطفح الجلدي، حقن الملتحمة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>التأثيرات العضلية والهيكلية:</em></p></td><td style="vertical-align:top"><p dir="RTL">الألم العضلي الهيكلي بما في ذلك تشنجات العضلات، الألم المفصليّ</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>الجهاز العصبي/الطب النفسي:</em></p></td><td style="vertical-align:top"><p dir="RTL">نوبة صرع كبرى؛ الاضطرابات النفسية التي يمكن التعافي منها في الحالات التي خضعت للمتابعة، بما في ذلك الهلوسة، الارتباك، التهيج، الاكتئاب، القلق، انخفاض الرغبة الجنسية؛ التنميل؛ الأرق؛ النعاس. تم الإبلاغ عن حدوث تشنجات لدى المرضى الذين يعانون من ضعف وظائف الكلى، في حالات نادرة جداً.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>الجهاز التنفسي:</em></p></td><td style="vertical-align:top"><p dir="RTL">التشنج القصبي، الالتهاب الرئوي الخلالي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>البشرة:</em></p></td><td style="vertical-align:top"><p dir="RTL">تقشر الأنسجة المتموتة البشروية التسممي/متلازمة ستيفنز جونسون (نادر جداً)، الثعلبة، حب الشباب، الحَكَّة، جفاف البشرة، الاحمرار</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>الحواس الخاصة:</em></p></td><td style="vertical-align:top"><p dir="RTL">طنين الأذن، اضطراب التذوق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>أخرى:</em></p></td><td style="vertical-align:top"><p dir="RTL">تم الإبلاغ عن حالات نادرة من الضعف الجنسي وتثدّي الرجل، إلا أنه في التجارب السريرية المضبوطة لم تكن الحوادث أكبر من تلك التي شوهدت مع الدواء الوهمي.</p></td></tr></tbody></table><p dir="RTL">قد تحدث التفاعلات الضائرة المُبلغ عنها لأقراص فاموتيدين أيضاً مع فاموتيدين للمعلق الفموي وحقن فاموتيدين. بالإضافة إلى ذلك، لوحظ تهيج عابر في موضع الحقن عند إعطاء حقن فاموتيدين.</p><p dir="RTL"><em>المرضى الأطفال</em></p><p dir="RTL">في دراسة سريرية أجريت على 35 مريضاً من الأطفال تقل أعمارهم عن عام واحد ويعانون من أعراض الارتجاع المعدي المريئي [على سبيل المثال، القيء (البصق)، التهيج (الانزعاج)]، لوحظ الاضطراب لدى 5 مرضى يتم علاجهم باستخدام فاموتيدين والذي تلاشى بعد التوقف عن تناول الدواء.</p><p dir="RTL">يرجى إخبار طبيبك، مقدم الرعاية الصحية أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة أو في حال ظهور أية آثار جانبية لم تذكر في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ داخل الثلاجة (2-8&deg; مئوية).</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL"><em>بعد التخفيف: </em></p><p dir="RTL">أثبتت حقنة فامودين المخففة استقراراً فيزيائياً وكيميائياً لمدة 7 أيام عند درجة حرارة الغرفة. على الرغم من أن حقنة فامودين المخففة قد أثبتت استقراراً فيزيائياً وكيميائياً لمدة 7 أيام عند درجة حرارة الغرفة، إلا أنه لا تتوفر بيانات بشأن الحفاظ على التعقيم بعد التخفيف. لذلك، في حالة عدم الاستخدام بعد التحضير مباشرةً، يوصى بحفظ المحاليل المخففة من حقن فامودين في الثلاجة واستخدامها خلال 48 ساعة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">ينبغي فحص الأدوية المعطاة عن طريق الحقن بصرياً بحثاً عن المواد الجزيئية الدقيقة وتغيّر اللون قبل إعطائها في حالة سمح المحلول والوعاء بذلك.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فاموتيدين.</p><p dir="RTL">يحتوي كل 2 مللتر من فامودين 20 ملغم/2 مللتر مركز للتخفيف للحقن على 20 ملغم فاموتيدين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي حمض الأسبارتيك، مانيتول وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فامودين 20 ملغم/2 مللتر مركز للتخفيف للحقن هو محلول شفاف، عديم اللون إلى مائل للأصفر قليلاً في أمبولات بحجم 2 مللتر من النوع رقم واحد شفافة مع نقطة كسر سوداء.</p><p dir="RTL">حجم العبوة: 5 أمبولات (2 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق ومحرر التشغيلة</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي</strong></p><p>شركة الحكمة إيطاليا المساهمة العامة المحدودة<br />طريق سيرتوزا، 10<br />27100 بافيا، إيطاليا<br />هاتف: 1751844 (0382-39) +/ 1751801 (0382-39) +<br />فاكس: 422745 (0382-39) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p>المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p>الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 03/2023؛ رقم النسخة SA1.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famodine 20 mg/2 ml Concentrate for Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ampoule of Famodine 20 mg/2 ml Concentrate for Solution for Injection contains 20 mg famotidine.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for injection.

Clear, colorless to slightly yellow solution. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Famodine, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. Famodine is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions:</p><ul><li><em>Short term treatment of active duodenal ulcer. </em>Most adult patients heal within 4 weeks; there is rarely reason to use Famodine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks.</li><li><em>Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. </em>Controlled studies in adults have not extended beyond one year.</li><li><em>Short term treatment of active benign gastric ulcer. </em>Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks.</li><li><em>Short term treatment of gastroesophageal reflux disease (GERD). </em>Famodine is indicated for short term treatment of patients with symptoms of GERD.</li><li>Famodine is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy.</li><li><em>Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas</em></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or in patients who are unable to take oral medication, Famodine may be administered until oral therapy can be instituted.</p><p>The recommended dosage for Famodine in adult patients is 20 mg intravenously q 12 h.</p><p>The doses and regimen for parenteral administration in patients with GERD have not been established.</p><p><strong>Dosage for Pediatric Patients &lt; 1 year of age Gastroesophageal Reflux Disease (GERD)</strong></p><p>See Special warnings and precautions for use, Pediatric Patients &lt; 1 year of age.</p><p>The studies described in PRECAUTIONS, Pediatric Patients &lt; 1 year of age suggest the following starting doses in pediatric patients &lt; 1 year of age: Gastroesophageal Reflux Disease (GERD) - 0.5 mg/kg/dose of famotidine oral suspension for the treatment of GERD for up to 8 weeks once daily in patients &lt; 3 months of age and 0.5 mg/kg/dose twice daily in patients 3 months to &lt; 1 year of age. Patients should also be receiving conservative measures (e.g., thickened feedings). The use of intravenous famotidine in pediatric patients &lt; 1 year of age with GERD has not been adequately studied.</p><p><strong>Dosage for Pediatric Patients 1-16 years of age</strong></p><p>See Special warnings and precautions for use, Pediatric Patients 1-16 years of age.</p><p>The studies described in PRECAUTIONS, Pediatric Patients 1-16 years of age suggest that the starting dose in pediatric patients 1-16 years of age is 0.25 mg/kg intravenously (injected over a period of not less than two minutes or as a 15-minute infusion) q 12 h up to 40 mg/day.</p><p>While published uncontrolled clinical studies suggest effectiveness of famotidine in the treatment of peptic ulcer, data in pediatric patients are insufficient to establish percent response with dose and duration of therapy. Therefore, treatment duration (initially based on adult duration recommendations) and dose should be individualized based on clinical response and/or gastric pH determination and endoscopy. Published uncontrolled studies in pediatric patients 1-16 years of age have demonstrated gastric acid suppression with doses up to 0.5 mg/kg intravenously q 12 h.</p><p><strong>Dosage Adjustments for Patients with Moderate or Severe Renal Insufficiency</strong></p><p>In adult patients with moderate (creatinine clearance &lt; 50 ml/min) or severe (creatinine clearance &lt; 10 ml/min) renal insufficiency, the elimination half-life of famotidine is increased. For patients with severe renal insufficiency, it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the drug in patients with moderate or severe renal insufficiency, the dose of Famodine may be reduced to half the dose, or the dosing interval may be prolonged to 36-48 hours as indicated by the patient&#39;s clinical response.</p><p>Based on the comparison of pharmacokinetic parameters for famotidine in adults and pediatric patients, dosage adjustment in pediatric patients with moderate or severe renal insufficiency should be considered.</p><p><strong>Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome, Multiple Endocrine Adenomas)</strong></p><p>The dosage of Famodine in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult intravenous dose is 20 mg q 12 h. Doses should be adjusted to individual patient needs and should continue as long as clinically indicated. In some patients, a higher starting dose may be required. Oral doses up to 160 mg q 6 h have been administered to some adult patients with severe Zollinger-Ellison Syndrome.</p><p><strong>Preparation of the Solution</strong></p><p>To prepare Famodine intravenous solutions, aseptically dilute 2 ml of Famodine Injection (solution containing 10 mg/ml) with 0.9% sodium chloride injection or other compatible intravenous solution (see Stability) to a total volume of either 5 ml or 10 ml and inject over a period of not less than 2 minutes.</p><p>To prepare Famodine intravenous infusion solutions, aseptically dilute 2 ml of Famodine Injection with 100 ml of 5% dextrose or other compatible intravenous solution (see Stability) and infuse over a 15&ndash;30-minute period.</p><p><strong>Concomitant Use of Antacids</strong></p><p>Antacids may be given concomitantly if needed.</p><p><strong>Stability</strong></p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p><p>When added to or diluted with most commonly used intravenous solutions, e.g., water for injection, 0.9% sodium chloride injection, 5% and 10% dextrose injection, or lactated ringer&#39;s injection, diluted famodine Injection is physically and chemically stable (i.e., maintains at least 90% of initial potency) for 7 days at room temperature &mdash; see Special Precautions for Storage.</p><p>When added to or diluted with 5% sodium bicarbonate injection, Famodine injection at a concentration of 0.2 mg/ml (the recommended concentration of Famodine intravenous infusion solutions) is physically and chemically stable (i.e., maintains at least 90% of initial potency) for 7 days at room temperature &mdash; see Special Precautions for Storage. However, a precipitate may form at higher concentrations of Famodine injection (&gt; 0.2 mg/ml) in 5% Sodium Bicarbonate Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to any component of these products. Cross sensitivity in this class of compounds has been observed. Therefore, famotidine should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>General</em></p><p>Symptomatic response to therapy with famotidine does not preclude the presence of gastric malignancy.</p><p><em>Patients with Moderate or Severe Renal Insufficiency</em></p><p>Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, longer intervals between doses or lower doses may need to be used in patients with moderate (creatinine clearance &lt; 50 ml/min) or severe (creatinine clearance &lt; 10 ml/min) renal insufficiency to adjust for the longer elimination half-life of famotidine (see Pharmacodynamic properties and Posology and method of administration).</p><p><em>Drug Interactions</em></p><p>No drug interactions have been identified. Studies with famotidine in man, in animal models, and <em>in vitro </em>have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.</p><p><em>Carcinogenesis, Mutagenesis, Impairment of Fertility</em></p><p>In a 106 week study in rats and a 92 week study in mice given oral doses of up to 2000 mg/kg/day (approximately 2500 times the recommended human dose for active duodenal ulcer), there was no evidence of carcinogenic potential for famotidine.</p><p>Famotidine was negative in the microbial mutagen test (Ames test) using <em>Salmonella typhimurium </em>and <em>Escherichia coli </em>with or without rat liver enzyme activation at concentrations up to 10,000 mcg/plate. In <em>in vivo </em>studies in mice, with a micronucleus test and a chromosomal aberration test, no evidence of a mutagenic effect was observed.</p><p>In studies with rats given oral doses of up to 2000 mg/kg/day or intravenous doses of up to 200 mg/kg/day, fertility and reproductive performance were not affected.</p><p><em>Pregnancy</em></p><p>Pregnancy Category B</p><p>Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and</p><p>500 mg/kg/day, respectively, and in both species at I.V. doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (250 times the usual human dose) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p><em>Nursing Mothers</em></p><p>Studies performed in lactating rats have shown that famotidine is secreted into breast milk. Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of at least 600 times the usual human dose. Famotidine is detectable in human milk. Because of the potential for serious adverse reactions in nursing infants from famotidine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p><p><em>Pediatric Patients &lt; 1 year of age</em></p><p>Use of famotidine in pediatric patients &lt; 1 year of age is supported by evidence from adequate and well-controlled studies of famotidine in adults, and by the following studies in pediatric patients &lt; 1 year of age.</p><p>Two pharmacokinetic studies in pediatric patients &lt; 1 year of age (N=48) demonstrated that clearance of famotidine in patients &gt;3 months to 1 year of age is similar to that seen in older pediatric patients (1-15 years of age) and adults. In contrast, pediatric patients 0-3 months of age had famotidine clearance values that were 2-to 4-fold less than those in older pediatric patients and adults. These studies also show that the mean bioavailability in pediatric patients &lt; 1 year of age after oral dosing is similar to older pediatric patients and adults. Pharmacodynamic data in pediatric patients 0-3 months of age suggest that the duration of acid suppression is longer compared with older pediatric patients, consistent with the longer famotidine half-life in pediatric patients 0-3 months of age.</p><p>In a double-blind, randomized, treatment-withdrawal study, 35 pediatric patients &lt; 1 year of age who were diagnosed as having gastroesophageal reflux disease were treated for up to 4 weeks with famotidine oral suspension (0.5 mg/kg/dose or 1 mg/kg/dose). Although an intravenous famotidine formulation was available, no patients were treated with intravenous famotidine in this study. Also, caregivers were instructed to provide conservative treatment including thickened feedings. Enrolled patients were diagnosed primarily by history of vomiting (spitting up) and irritability (fussiness). The famotidine dosing regimen was once daily for patients &lt; 3 months of age and twice daily for patients &ge;3 months of age. After 4 weeks of treatment, patients were randomly withdrawn from the treatment and followed an additional 4 weeks for adverse events and symptomatology. Patients were evaluated for vomiting (spitting up), irritability (fussiness) and global assessments of improvement. The study patients ranged in age at entry from 1.3 to 10.5 months (mean 5.6 &plusmn; 2.9 months), 57% were female, 91% were white and 6% were black. Most patients (27/35) continued into the treatment withdrawal phase of the study. Two patients discontinued famotidine due to adverse events. Most patients improved during the initial treatment phase of the study. Results of the treatment withdrawal phase were difficult to interpret because of small numbers of patients. Of the 35 patients enrolled in the study, agitation was observed in 5 patients on famotidine that resolved when the medication was discontinued; agitation was not observed in patients on placebo (see Undesirable Effects, Pediatric Patients).</p><p>These studies suggest that a starting dose of 0.5 mg/kg/dose of famotidine oral suspension may be of benefit for the treatment of GERD for up to 4 weeks once daily in patients &lt; 3 months of age and twice daily in patients 3 months to &lt; 1 year of age; the safety and benefit of famotidine treatment beyond 4 weeks have not been established. Famotidine should be considered for the treatment of GERD only if conservative measures (e.g., thickened feedings) are used concurrently and if the potential benefit outweighs the risk.</p><p><em>Pediatric Patients 1-16 years of age</em></p><p>Use of famotidine in pediatric patients 1-16 years of age is supported by evidence from adequate and wellcontrolled studies of famotidine in adults, and by the following studies in pediatric patients: In published studies in small numbers of pediatric patients 1-15 years of age, clearance of famotidine was similar to that seen in adults.</p><p>In pediatric patients 11-15 years of age, oral doses of 0.5 mg/kg were associated with a mean area under the curve (AUC) similar to that seen in adults treated orally with 40 mg. Similarly, in pediatric patients 1-15 years of age, intravenous doses of 0.5 mg/kg were associated with a mean AUC similar to that seen in adults treated intravenously with 40 mg. Limited published studies also suggest that the relationship between serum concentration and acid suppression is similar in pediatric patients 1-15 years of age as compared with adults.</p><p>These studies suggest that the starting dose for pediatric patients 1-16 years of age is 0.25 mg/kg intravenously (injected over a period of not less than two minutes or as a 15-minute infusion) q 12 h up to 40 mg/day. While published uncontrolled clinical studies suggest effectiveness of famotidine in the treatment of peptic ulcer, data in pediatric patients are insufficient to establish percent response with dose and duration of therapy.</p><p>Therefore, treatment duration (initially based on adult duration recommendations) and dose should be individualized based on clinical response and/or gastric pH determination and endoscopy. Published uncontrolled studies in pediatric patients have demonstrated gastric acid suppression with doses up to 0.5 mg/kg intravenously q 12 h.</p><p><em>Geriatric Use</em></p><p>Of the 4,966 subjects in clinical studies who were treated with famotidine, 488 subjects (9.8%) were 65 and older, and 88 subjects (1.7%) were greater than 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, greater sensitivity of some older patients cannot be ruled out.</p><p>No dosage adjustment is required based on age. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Dosage adjustment in the case of moderate or severe renal impairment is necessary (see Special warnings and precautions for use, Patients with Moderate or Severe Renal Insufficiency and Dosage and Administration, Dosage Adjustment for Patients with Moderate or Severe Renal Insufficiency).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No drug interactions have been identified. Studies with famotidine in man, in animal models, and <em>in vitro </em>have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p><em>Pregnancy Category B</em></p><p>Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and</p><p>500 mg/kg/day, respectively, and in both species at I.V. doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (250 times the usual human dose) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p><strong>Nursing Mothers</strong></p><p>Studies performed in lactating rats have shown that famotidine is secreted into breast milk. Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of at least 600 times the usual human dose. Famotidine is detectable in human milk. Because of the potential for serious adverse reactions in nursing infants from famotidine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions listed below have been reported during domestic and international clinical trials in approximately 2500 patients. In those controlled clinical trials in which famotidine tablets were compared to placebo, the incidence of adverse experiences in the group which received famotidine tablets, 40 mg at bedtime, was similar to that in the placebo group.</p><p>The following adverse reactions have been reported to occur in more than 1% of patients on therapy with famotidine in controlled clinical trials, and may be causally related to the drug: headache (4.7%), dizziness (1.3%), constipation (1.2%) and diarrhea (1.7%).</p><p>The following other adverse reactions have been reported infrequently in clinical trials or since the drug was marketed. The relationship to therapy with famotidine has been unclear in many cases. Within each category the adverse reactions are listed in order of decreasing severity:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Body as a Whole:</em></p></td><td style="vertical-align:top"><p>Fever, asthenia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiovascular:</em></p></td><td style="vertical-align:top"><p>Arrhythmia, AV block, palpitation</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal:</em></p></td><td style="vertical-align:top"><p>Cholestatic jaundice, liver enzyme abnormalities, vomiting, nausea, abdominal discomfort,</p><p>anorexia, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p><em>Hematologic:</em></p></td><td style="vertical-align:top"><p>Rare cases of agranulocytosis, pancytopenia, leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Hypersensitivity:</em></p></td><td style="vertical-align:top"><p>Anaphylaxis, angioedema, orbital or facial edema, urticaria, rash, conjunctival injection</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal:</em></p></td><td style="vertical-align:top"><p>Musculoskeletal pain including muscle cramps, arthralgia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous System/Psychiatric:</em></p></td><td style="vertical-align:top"><p>Grand mal seizure; psychic disturbances, which were reversible in cases for which follow-up was obtained, including hallucinations, confusion, agitation, depression, anxiety, decreased libido; paresthesia; insomnia; somnolence. Convulsions, in patients with impaired renal function, have been reported very rarely.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory:</em></p></td><td style="vertical-align:top"><p>Bronchospasm, interstitial pneumonia</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin:</em></p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis/Stevens Johnson syndrome (very rare), alopecia, acne, pruritus, dry skin, flushing</p></td></tr><tr><td style="vertical-align:top"><p><em>Special Senses:</em></p></td><td style="vertical-align:top"><p>Tinnitus, taste disorder</p></td></tr><tr><td style="vertical-align:top"><p><em>Other:</em></p></td><td style="vertical-align:top"><p>Rare cases of impotence and rare cases of gynecomastia have been reported; however, in controlled clinical trials, the incidences were not greater than those seen with placebo.</p></td></tr></tbody></table><p>The adverse reactions reported for famotidine tablets may also occur with famotidine for oral suspension, famotidine injection. In addition, transient irritation at the injection site has been observed with famotidine injection.</p><p><em>Pediatric Patients</em></p><p>In a clinical study in 35 pediatric patients &lt; 1 year of age with GERD symptoms [e.g., vomiting (spitting up), irritability (fussing)], agitation was observed in 5 patients on famotidine that resolved when the medication was discontinued.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https: //ade.sfda.gov.sa</p><p>Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions in overdose cases are similar to the adverse reactions encountered in normal clinical experience (see Undesirable Effects).<strong> </strong>Oral doses of up to 640 mg/day have been given to adult patients with pathological hypersecretory conditions with no serious adverse effects. In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed.</p><p>The intravenous LD<sub>50</sub> of famotidine for mice and rats ranged from 254-563 mg/kg and the minimum lethal single I.V. dose in dogs was approximately 300 mg/kg. Signs of acute intoxication in I.V. treated dogs were emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse. The oral LD<sub>50</sub> of famotidine in male and female rats and mice was greater than 3000 mg/kg and the minimum lethal acute oral dose in dogs exceeded 2000 mg/kg. Famotidine did not produce overt effects at high oral doses in mice, rats, cats and dogs, but induced significant anorexia and growth depression in rabbits starting with 200 mg/kg/day orally.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The active ingredient in Famodine (famotidine) injection is a histamine H<sub>2</sub>-receptor antagonist. Famotidine is <em>N&#39;</em>-(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4- thiazolyl] methyl] thio] propanimidamide.</p><p><strong>GI Effects</strong></p><p>Famotidine is a competitive inhibitor of histamine H<sub>2</sub>-receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.</p><p>In normal volunteers and hypersecretors, famotidine inhibited basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration, the onset of the antisecretory effect occurred within one hour; the maximum effect was dose-dependent, occurring within one to three hours.</p><p>Duration of inhibition of secretion by doses of 20 and 40 mg was 10 to 12 hours.</p><p>After intravenous administration, the maximum effect was achieved within 30 minutes. Single intravenous doses of 10 and 20 mg inhibited nocturnal secretion for a period of 10 to 12 hours. The 20 mg dose was associated with the longest duration of action in most subjects.</p><p>Single evening oral doses of 20 and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid secretion in all subjects. The mean suppression was 76% and 84%, respectively, 3 to 5 hours after administration, and 25% and 30%, respectively, 8 to 10 hours after administration. In some subjects who received the 20 mg dose, however, the antisecretory effect was dissipated within 6-8 hours. There was no cumulative effect with repeated doses. The nocturnal intragastric pH was raised by evening doses of 20 and 40 mg of famotidine to mean values of 5.0 and 6.4, respectively. When famotidine was given after breakfast, the basal daytime interdigestive pH at 3 and 8 hours after 20 or 40 mg of famotidine was raised to about 5.</p><p>Famotidine had little or no effect on fasting or postprandial serum gastrin levels. Gastric emptying and exocrine pancreatic function were not affected by famotidine.</p><p><strong>Other Effects</strong></p><p>Systemic effects of famotidine in the CNS, cardiovascular, respiratory or endocrine systems were not noted in clinical pharmacology studies. Also, no antiandrogenic effects were noted. (See Undesirable effects). Serum hormone levels, including prolactin, cortisol, thyroxine (T<sub>4</sub>), and testosterone, were not altered after treatment with famotidine.</p><p><strong>Clinical Studies</strong></p><p>The majority of clinical study experience involved oral administration of famotidine tablets, and is provided herein for reference.</p><p><em>Duodenal Ulcer</em></p><p>In a U.S. multicenter, double-blind study in outpatients with endoscopically confirmed duodenal ulcer, orally administered famotidine was compared to placebo. As shown in Table 1, 70% of patients treated with famotidine 40 mg h.s. were healed by week 4.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 1</p><p>Outpatients with Endoscopically</p><p>Confirmed Healed Duodenal Ulcers</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Famotidine 40 mg h.s.</p><p>(N=89)</p></td><td style="vertical-align:top"><p>Famotidine 20 mg b.i.d.</p><p>(N=84)</p></td><td style="vertical-align:top"><p>Placebo h.s.</p><p>(N=97)</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>**32%</p></td><td style="vertical-align:top"><p>**38%</p></td><td style="vertical-align:top"><p>17%</p></td></tr><tr><td style="vertical-align:top"><p>Week 4</p></td><td style="vertical-align:top"><p>**70%</p></td><td style="vertical-align:top"><p>**67%</p></td><td style="vertical-align:top"><p>31%</p></td></tr></tbody></table><p>** Statistically significantly different than placebo (p&lt;0.001)</p><p>Patients not healed by week 4 were continued in the study. By week 8, 83% of patients treated with famotidine had healed versus 45% of patients treated with placebo. The incidence of ulcer healing with famotidine was significantly higher than with placebo at each time point based on proportion of endoscopically confirmed healed ulcers.</p><p>In this study, time to relief of daytime and nocturnal pain was significantly shorter for patients receiving famotidine than for patients receiving placebo; patients receiving famotidine also took less antacid than the patients receiving placebo.</p><p><strong>Long-Term Maintenance</strong></p><p><em>Treatment of Duodenal Ulcers</em></p><p>Famotidine, 20 mg p.o. h.s. was compared to placebo h.s. as maintenance therapy in two double-blind, multicenter studies of patients with endoscopically confirmed healed duodenal ulcers. In the U.S. study the observed ulcer incidence within 12 months in patients treated with placebo was 2.4 times greater than in the patients treated with famotidine. The 89 patients treated with famotidine had a cumulative observed ulcer incidence of 23.4% compared to an observed ulcer incidence of 56.6% in the 89 patients receiving placebo (p&lt;0.01).</p><p>These results were confirmed in an international study where the cumulative observed ulcer incidence within 12 months in the 307 patients treated with famotidine was 35.7%, compared to an incidence of 75.5% in the 325 patients treated with placebo (p&lt;0.01).</p><p><em>Gastric Ulcer</em></p><p>In both a U.S. and an international multicenter, double-blind study in patients with endoscopically confirmed active benign gastric ulcer, orally administered famotidine, 40 mg h.s., was compared to placebo h.s. Antacids were permitted during the studies, but consumption was not significantly different between the famotidine and placebo groups. As shown in Table 2, the incidence of ulcer healing (dropouts counted as unhealed) with famotidine was statistically significantly better than placebo at weeks 6 and 8 in the U.S. study, and at weeks 4, 6 and 8 in the international study, based on the number of ulcers that healed, confirmed by endoscopy.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Table 2</p><p>Patients with Endoscopically</p><p>Confirmed Healed Gastric Ulcers</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>U.S. Study</p></td><td colspan="2" style="vertical-align:top"><p>International Study</p></td></tr><tr><td style="vertical-align:top"><p>Famotidine 40 mg h.s.</p><p>(N=74)</p></td><td style="vertical-align:top"><p>Placebo h.s.</p><p>(N=75)</p></td><td style="vertical-align:top"><p>Famotidine 40 mg h.s.</p><p>(N=149)</p></td><td style="vertical-align:top"><p>Placebo h.s.</p><p>(N=145)</p></td></tr><tr><td style="vertical-align:top"><p>Week 4</p></td><td style="vertical-align:top"><p>45%</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>&dagger;47%</p></td><td style="vertical-align:top"><p>31%</p></td></tr><tr><td style="vertical-align:top"><p>Week 6</p></td><td style="vertical-align:top"><p>&dagger;66%</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>&dagger;65%</p></td><td style="vertical-align:top"><p>46%</p></td></tr><tr><td style="vertical-align:top"><p>Week 8</p></td><td style="vertical-align:top"><p>***78%</p></td><td style="vertical-align:top"><p>64%</p></td><td style="vertical-align:top"><p>&dagger;80%</p></td><td style="vertical-align:top"><p>54%</p></td></tr></tbody></table></td></tr></tbody></table><p>***,&dagger; Statistically significantly better than placebo (p&le;0.05, p&le;0.01 respectively)</p><p>Time to complete relief of daytime and nighttime pain was statistically significantly shorter for patients receiving famotidine than for patients receiving placebo; however, in neither study was there a statistically significant difference in the proportion of patients whose pain was relieved by the end of the study (week 8).</p><p><em>Gastroesophageal Reflux Disease (GERD)</em></p><p>Orally administered famotidine was compared to placebo in a U.S. study that enrolled patients with symptoms of GERD and without endoscopic evidence of erosion or ulceration of the esophagus. Famotidine 20 mg b.i.d. was statistically significantly superior to 40 mg h.s. and to placebo in providing a successful symptomatic outcome, defined as moderate or excellent improvement of symptoms (Table 3).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 3</p><p>% Successful Symptomatic Outcome</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Famotidine 20 mg b.i.d.</p><p>(N=154)</p></td><td style="vertical-align:top"><p>Famotidine 40 mg h.s.</p><p>(N=149)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=73)</p></td></tr><tr><td style="vertical-align:top"><p>Week 6</p></td><td style="vertical-align:top"><p>82&dagger;&dagger;</p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>62</p></td></tr></tbody></table></td></tr></tbody></table><p>&dagger;&dagger; p&le;0.01 vs Placebo</p><p>By two weeks of treatment, symptomatic success was observed in a greater percentage of patients taking famotidine 20 mg b.i.d. compared to placebo (p&le;0.01).</p><p>Symptomatic improvement and healing of endoscopically verified erosion and ulceration were studied in two additional trials. Healing was defined as complete resolution of all erosions or ulcerations visible with endoscopy. The U.S. study comparing famotidine 40 mg p.o. b.i.d. to placebo and famotidine 20 mg p.o. b.i.d., showed a significantly greater percentage of healing for famotidine 40 mg b.i.d. at weeks 6 and 12 (Table 4).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 4</p><p>% Endoscopic Healing - U.S. Study</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Famotidine 40 mg b.i.d.</p><p>(N=127)</p></td><td style="vertical-align:top"><p>Famotidine 20 mg b.i.d.</p><p>(N=125)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=66)</p></td></tr><tr><td style="vertical-align:top"><p>Week 6</p></td><td style="vertical-align:top"><p>48&dagger;&dagger;&dagger;,&Dagger;&Dagger;</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>69&dagger;&dagger;&dagger;,&Dagger;</p></td><td style="vertical-align:top"><p>54&dagger;&dagger;&dagger;</p></td><td style="vertical-align:top"><p>29</p></td></tr></tbody></table><p>&dagger;&dagger;&dagger; p&le;0.01 vs Placebo</p><p>&Dagger; p&le;0.05 vs famotidine 20 mg b.i.d.</p><p>&Dagger;&Dagger; p&le;0.01 vs famotidine 20 mg b.i.d.</p><p>As compared to placebo, patients who received famotidine had faster relief of daytime and nighttime heartburn and a greater percentage of patients experienced complete relief of nighttime heartburn. These differences were statistically significant.</p><p>In the international study, when famotidine 40 mg p.o. b.i.d. was compared to ranitidine 150 mg p.o. b.i.d., a statistically significantly greater percentage of healing was observed with famotidine 40 mg b.i.d. at week 12 (Table 5). There was, however, no significant difference among treatments in symptom relief.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 5</p><p>% Endoscopic Healing - International Study</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Famotidine 40 mg b.i.d.</p><p>(N=175)</p></td><td style="vertical-align:top"><p>Famotidine 20 mg b.i.d.</p><p>(N=93)</p></td><td style="vertical-align:top"><p>Ranitidine 150 mg b.i.d.</p><p>(N=172)</p></td></tr><tr><td style="vertical-align:top"><p>Week 6</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>42</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>71&Dagger;&Dagger;&Dagger;</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>60</p></td></tr></tbody></table></td></tr></tbody></table><p>&Dagger;&Dagger;&Dagger; p&le;0.05 vs Ranitidine 150 mg b.i.d.</p><p><em>Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome, Multiple Endocrine Adenomas)</em></p><p>In studies of patients with pathological hypersecretory conditions such as Zollinger-Ellison Syndrome with or without multiple endocrine adenomas, famotidine significantly inhibited gastric acid secretion and controlled associated symptoms. Orally administered doses from 20 to 160 mg q 6 h maintained basal acid secretion below 10 mEq/hr; initial doses were titrated to the individual patient need and subsequent adjustments were necessary with time in some patients. famotidine was well tolerated at these high dose levels for prolonged periods (greater than 12 months) in eight patients, and there were no cases reported of gynecomastia, increased prolactin levels, or impotence which were considered to be due to the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong></p><p>Orally administered famotidine is incompletely absorbed and its bioavailability is 40-45%. famotidine undergoes minimal first-pass metabolism. After oral doses, peak plasma levels occur in 1-3 hours. Plasma levels after multiple doses are similar to those after single doses. Fifteen to 20% of famotidine in plasma is protein bound. famotidine has an elimination half-life of 2.5-3.5 hours. famotidine is eliminated by renal (65-70%) and metabolic (30-35%) routes. Renal clearance is 250-450 mL/min, indicating some tubular excretion. Twenty-five to 30% of an oral dose and 65-70% of an intravenous dose are recovered in the urine as unchanged compound. The only metabolite identified in man is the S-oxide.</p><p>There is a close relationship between creatinine clearance values and the elimination half-life of famotidine. In patients with severe renal insufficiency, i.e., creatinine clearance less than 10 mL/min, the elimination half-life of famotidine may exceed 20 hours and adjustment of dose or dosing intervals in moderate and severe renal insufficiency may be necessary (see Special Precautions for Storage, Posology and method of administration).</p><p>In elderly patients, there are no clinically significant age-related changes in the pharmacokinetics of famotidine. However, in elderly patients with decreased renal function, the clearance of the drug may be decreased (see Special Precautions for Storage, <em>Geriatric Use</em>).</p><p><strong>Pediatric patients </strong></p><p>Table 6 presents pharmacokinetic data from clinical trials and a published study in pediatric patients (&lt; 1 year of age; N=27) given famotidine I.V. 0.5 mg/kg and from published studies of small numbers of pediatric patients (1-15 years of age) given famotidine intravenously. Areas under the curve (AUCs) are normalized to a dose of 0.5 mg/kg I.V. for pediatric patients 1-15 years of age and compared with an extrapolated 40 mg intravenous dose in adults (extrapolation based on results obtained with a 20 mg I.V. adult dose).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Table 6</p><p>Pharmacokinetic Parameters<sup>a</sup> of Intravenous Famotidine</p></td></tr><tr><td style="vertical-align:top"><p>Age</p><p>(N=number of patients)</p></td><td style="vertical-align:top"><p>Area Under the Curve (AUC)</p><p>(ng-hr/mL)</p></td><td style="vertical-align:top"><p>Total Clearance (Cl)</p><p>(L/hr/kg)</p></td><td style="vertical-align:top"><p>Volume of Distribution (V<sub>d</sub>)</p><p>(L/kg)</p></td><td style="vertical-align:top"><p>Elimination Half-life (T<sub>1/2</sub>)</p><p>(hours)</p></td></tr><tr><td style="vertical-align:top"><p>0-1 month<sup>c</sup></p><p>(N=10)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>0.13 &plusmn; 0.06</p></td><td style="vertical-align:top"><p>1.4 &plusmn; 0.4</p></td><td style="vertical-align:top"><p>10.5 &plusmn; 5.4</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0-3 months<sup>d</sup></p><p>(N=6)</p></td><td style="vertical-align:top"><p>2688 &plusmn; 847</p></td><td style="vertical-align:top"><p>0.21 &plusmn; 0.06</p></td><td style="vertical-align:top"><p>1.8 &plusmn; 0.3</p></td><td style="vertical-align:top"><p>8.1 &plusmn; 3.5</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 3-12 months<sup>d</sup></p><p>(N=11)</p></td><td style="vertical-align:top"><p>1160 &plusmn; 474</p></td><td style="vertical-align:top"><p>0.49 &plusmn; 0.17</p></td><td style="vertical-align:top"><p>2.3 &plusmn; 0.7</p></td><td style="vertical-align:top"><p>4.5 &plusmn; 1.1</p></td></tr><tr><td style="vertical-align:top"><p>1-11 yrs (N=20)</p></td><td style="vertical-align:top"><p>1089 &plusmn; 834</p></td><td style="vertical-align:top"><p>0.54 &plusmn; 0.34</p></td><td style="vertical-align:top"><p>2.07 &plusmn; 1.49</p></td><td style="vertical-align:top"><p>3.38 &plusmn; 2.60</p></td></tr><tr><td style="vertical-align:top"><p>11-15 yrs (N=6)</p></td><td style="vertical-align:top"><p>1140 &plusmn; 320</p></td><td style="vertical-align:top"><p>0.48 &plusmn; 0.14</p></td><td style="vertical-align:top"><p>1.5 &plusmn; 0.4</p></td><td style="vertical-align:top"><p>2.3 &plusmn; 0.4</p></td></tr><tr><td style="vertical-align:top"><p>Adult (N=16)</p></td><td style="vertical-align:top"><p>1726<sup>b</sup></p></td><td style="vertical-align:top"><p>0.39 &plusmn; 0.14</p></td><td style="vertical-align:top"><p>1.3 &plusmn; 0.2</p></td><td style="vertical-align:top"><p>2.83 &plusmn; 0.99</p></td></tr></tbody></table><p><sup>a</sup>Values are presented as means &plusmn; SD unless indicated otherwise.</p><p><sup>b</sup>Mean value only.</p><p><sup>c</sup>Single center study.</p><p><sup>d</sup>Multicenter study.</p><p>Plasma clearance is reduced and elimination half-life is prolonged in pediatric patients 0-3 months of age compared to older pediatric patients. The pharmacokinetic parameters for pediatric patients, ages &gt; 3 months-15 years, are comparable to those obtained for adults.</p><p>Bioavailability studies of 8 pediatric patients (11-15 years of age) showed a mean oral bioavailability of 0.5 compared to adult values of 0.42 to 0.49. Oral doses of 0.5 mg/kg achieved AUCs of 645 &plusmn; 249 ng-hr/mL and 580 &plusmn; 60 ng-hr/mL in pediatric patients &lt;1 year of age (N=5) and in pediatric patients 11-15 years of age, respectively, compared to 482 &plusmn; 181 ng-hr/mL in adults treated with 40 mg orally.</p><p><em>Pharmacodynamics</em></p><p>Pharmacodynamics of famotidine were evaluated in 5 pediatric patients 2-13 years of age using the sigmoid E<sub>max</sub> model. These data suggest that the relationship between serum concentration of famotidine and gastric acid suppression is similar to that observed in one study of adults (Table 7).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Table 7</p><p>Pharmacodynamics of famotidine using the sigmoid E<sub>max</sub> model</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>EC<sub>50</sub> (ng/mL)<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Pediatric Patients</p></td><td style="vertical-align:top"><p>26 &plusmn; 13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Data from one study</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>a) healthy adult subjects</p></td><td style="vertical-align:top"><p>26.5 &plusmn; 10.3</p></td></tr><tr><td style="vertical-align:top"><p>b) adult patients with upper GI bleeding</p></td><td style="vertical-align:top"><p>18.7 &plusmn; 10.8</p></td></tr></tbody></table></td></tr></tbody></table><p>*Serum concentration of famotidine associated with 50% maximum gastric acid reduction. Values are presented as means &plusmn; SD.</p><p>Five published studies (Table 8) examined the effect of famotidine on gastric pH and duration of acid suppression in pediatric patients. While each study had a different design, acid suppression data over time are summarized as follows:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 8</p></td></tr><tr><td style="vertical-align:top"><p>Dosage</p></td><td style="vertical-align:top"><p>Route</p></td><td style="vertical-align:top"><p>Effect<sup>a</sup></p></td><td style="vertical-align:top"><p>Number of Patients</p><p>(age range)</p></td></tr><tr><td style="vertical-align:top"><p>0.5 mg/kg, single dose</p></td><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>gastric pH &gt; 4 for 19.5 hours (17.3, 21.8)<sup>c</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>11 (5-19 days)</p></td></tr><tr><td style="vertical-align:top"><p>0.3 mg/kg, single dose</p></td><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>gastric pH &gt;3.5 for 8.7 &plusmn; 4.7<sup>b</sup> hours</p></td><td style="vertical-align:top"><p>6 (2-7 years)</p></td></tr><tr><td style="vertical-align:top"><p>0.4-0.8 mg/kg</p></td><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>gastric pH &gt;4 for 6-9 hours</p></td><td style="vertical-align:top"><p>18 (2-69 months)</p></td></tr><tr><td style="vertical-align:top"><p>0.5 mg/kg, single dose</p></td><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>a &gt; 2 pH unit increase above baseline in gastric pH for &gt; 8 hours</p></td><td style="vertical-align:top"><p>9 (2-13 years)</p></td></tr><tr><td style="vertical-align:top"><p>0.5 mg/kg b.i.d.</p></td><td style="vertical-align:top"><p>I.V.</p></td><td style="vertical-align:top"><p>gastric pH &gt;5 for 13.5 &plusmn; 1.8<sup>b</sup> hours</p></td><td style="vertical-align:top"><p>4 (6-15 years)</p></td></tr><tr><td style="vertical-align:top"><p>0.5 mg/kg b.i.d.</p></td><td style="vertical-align:top"><p>oral</p></td><td style="vertical-align:top"><p>gastric pH &gt;5 for 5.0 &plusmn; 1.1<sup>b</sup> hours</p></td><td style="vertical-align:top"><p>4 (11-15 years)</p></td></tr></tbody></table></td></tr></tbody></table><p><sup>a</sup>Values reported in published literature.</p><p><sup>b</sup>Means &plusmn; SD.</p><p><sup>c</sup>Mean (95% confidence interval).</p><p>The duration of effect of famotidine I.V. 0.5 mg/kg on gastric pH and acid suppression was shown in one study to be longer in pediatric patients &lt; 1 month of age than in older pediatric patients. This longer duration of gastric acid suppression is consistent with the decreased clearance in pediatric patients &lt; 3 months of age (see Table 6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Aspartic acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

After dilution: 
Diluted Famodine injection is physically and chemically stable for 7 days at room temperature. Although diluted Famodine injection has been shown to be physically and chemically stable for 7 days at room temperature, there are no data on the maintenance of sterility after dilution. Therefore, it is recommended that if not used immediately after preparation, diluted solutions of Famodine injection should be refrigerated and used within 48 hours.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 ml type I clear glass ampoules with black one-point-cut</p><p>Pack size: 5 Ampoules (2 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07 March 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>